All In Biotech

NDA 020355 · Ferring Pharms INC

Stimate

Desmopressin Acetate · Nasal

OrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Mar 7, 1994

Approved uses

1

Original approval plus efficacy supplements

Registered trials

99

23 Phase 3, 8 recruiting

FAERS reports

2,425

1,645 serious, 150 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 22, 2026.

STIMATE is a vasopressin analog used for: Hemophilia A - for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.1 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) Limitations of Use STIMATE is not indicated for: von Willebrand’s disease (severe Type I) - not indicated for the treatment of patients with severe Type I von Willebrand’s disease and when there is evidence of an abnormal molecular form of factor VIII antigen. ( 1.2 ) 1.1 Hemophilia A STIMATE is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% without factor VIII antibodies to: Maintain hemostasis during surgical procedures and postoperatively Reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. 1.2 von Willebrand’s Disease (Type I) STIMATE is indicated for patients with mild to moderate von Willebrand’s disease (Type I) with factor VIII levels greater than 5% to: Maintain hemostasis during surgical procedures and postoperatively Reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, mucosal bleeding, or menorrhagia. Limitations of Use Desmopressin acetate is not indicated for the treatment of severe von Willebrand’s disease (Type I) and when there is evidence of an abnormal...

Mechanism: Desmopressin acetate increases plasma levels of factor VIII activity in patients with hemophilia and von Willebrand’s disease Type I.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • STIMATE · DESMOPRESSIN ACETATE 0.15MG/SPRAY · SPRAY, METERED, NASAL · Discontinued
  • STIMATE (NEEDS NO REFRIGERATION) · DESMOPRESSIN ACETATE 0.15MG/SPRAY · SPRAY, METERED, NASAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Desmopressin" as an intervention, any sponsor and status, largest first.

All 99 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hyponatraemia237
  • headache177
  • drug ineffective176
  • nausea125
  • fatigue102
  • off label use94
  • vomiting94
  • dizziness79
  • flushing67
  • pain66
  • diarrhoea61
  • epistaxis61

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200420
200521
200634
200734
2008113
200996
201095
201190
2012103
201342
201484
2015104
2016190
2017164
2018141
2019131
2020144
2021140
2022127
2023128
2024173
2025154
202697

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 604 on PubMed

Sponsor: Ferring Pharms INC · Also marketed as Stimate (Needs No Refrigeration)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.